

Efavirenz + emtricitabine + tenofovir



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: [J05AR06](#)

| | |
|--------------------------|--|
| Indication | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z |
| INN | Efavirenz + emtricitabine + tenofovir |
| Medicine type | Chemical agent |
| List type | Core |
| Formulations | Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) |
| EML status history | First added in 2007 (TRS 946) Changed in 2021 (TRS 1035) |
| Sex | All |
| Age | Adolescents and adults |
| Therapeutic alternatives | efavirenz + lamivudine + tenofovir (ATC codes: J05AR11) |
| Patent information | Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org ↗ Read more about patents. ↗ |

Wikipedia [Efavirenz + emtricitabine + tenofovir](#) [↗](#)

DrugBank [Efavirenz](#) [↗](#),
[Emtricitabine](#) [↗](#),
[Tenofovir disoproxil](#) [↗](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.

